Press release
PARP Inhibitors Market is Driven by Rising Cancer Incidence and Precision Oncology Advancements | AstraZeneca, Pfizer Inc., GSK plc, Pharmaand GmbH.
The Global PARP Inhibitors Market reached US$ 3.53 billion in 2023 and is expected to reach US$ 6.64 billion by 2031, growing at a CAGR of 8.3% during the forecast period 2024-2031.The latest PARP Inhibitors Market Report by DataM Intelligence offers a clear analysis of global trends, market size, key players, and growth drivers. Covering emerging technologies, evolving care models, and regulatory insights, it provides strategic intelligence to help stakeholders navigate the dynamic healthcare landscape through 2025-2033
Download exclusive insights with our detailed sample report (Corporate Email ID gets priority access):
https://www.datamintelligence.com/download-sample/parp-inhibitors-market?ophp
PARP inhibitors are targeted cancer therapies that block poly (ADP-ribose) polymerase enzymes, disrupting DNA repair in cancer cells-particularly effective in BRCA-mutated cancers. The market is expanding with increasing approvals for breast, ovarian, prostate, and pancreatic cancers, and ongoing clinical trials exploring broader oncology applications.
PARP Inhibitors Market Competitors Overview:
Market Companies:
The major global players in the PARP inhibitors market include AstraZeneca, Pfizer Inc., GSK plc, Pharmaand GmbH., Globela Pharma, Johnson & Johnson Services, Inc., Merck & Co., Inc., Beacon Pharmaceuticals PLC, and EVEREST among others.
Emerging Players:
The emerging players in the global PARP inhibitors market include Artios Pharma, Repare Therapeutics, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and ONO PHARMACEUTICAL CO., LTD. among others.
Important Industry Updates of 2024 and 2025:
✅ In July 2024, AstraZeneca announced the DUO-O Phase III trial investigated the combination of Lynparza (olaparib) and Imfinzi (durvalumab) with chemotherapy and bevacizumab in newly diagnosed patients with advanced high-grade epithelial ovarian cancer who do not have tumor BRCA mutations.
PARP Inhibitors Market Segments Overview:
∎ By Product Type (Olaparib, Niraparib, Rucaparib, Talazoparib, Others)
∎ By Application (Breast Cancer, Ovarian Cancer, Prostate Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Others)
∎ By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/parp-inhibitors-market?ophp
Methodology and Scope:
This PARP Inhibitors Market report is developed using a robust research methodology that combines primary interviews, insights from industry experts, and verified secondary sources such as company filings, trade journals, and trusted databases. It follows a bottom-up and top-down approach to ensure data accuracy through triangulation. The scope of the report covers current market trends, growth potential, and strategic developments across global and regional markets.
Regional Overview for PARP Inhibitors Market:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Looking For Exclusive Full Report? Get it here: https://www.datamintelligence.com/buy-now-page?report=parp-inhibitors-market?ophp
The Report Includes:
➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.
➡ Go-to-market Strategy.
➡ Neutral perspective on the market performance.
➡ Customized regional/country reports as per request and country level analysis.
➡ Potential & niche segments and regions exhibiting promising growth covered.
People Also Ask:
➤ What are the global sales, production, import, and export trends in the PARP Inhibitors market?
➤ Who are the top manufacturers, and what are their output, pricing, and revenue figures?
➤ What key opportunities and challenges do vendors face in this market?
➤ Which product types, applications, or end-users are driving growth and holding market share?
➤ What are the main growth drivers and restraints affecting the PARP Inhibitors market?
Unlock 360° Market Intelligence with DataM Subscription Services:
https://www.datamintelligence.com/reports-subscription
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drugs Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release PARP Inhibitors Market is Driven by Rising Cancer Incidence and Precision Oncology Advancements | AstraZeneca, Pfizer Inc., GSK plc, Pharmaand GmbH. here
News-ID: 4104116 • Views: …
More Releases from DataM intelligence 4 Market Research LLP
United States Fiberglass Flooring Market Size, Share, Trends, and Forecast 2024- …
Market Size and Growth
Global Fiberglass Flooring Market reached US$ 784.6 million in 2022 and is expected to reach US$ 1254.4 million by 2031, growing with a CAGR of 6.1% during the forecast period 2024-2031.
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/fiberglass-flooring-market?juli
Key Developments
United States: Recent Industry Developments
✅ In November 2025, major U.S. flooring manufacturers expanded fiberglass-backed vinyl production capacity to meet surging demand…
Japan Coriander Oil Market Forecast 2025-2033: Market Size, Growth Trends & Lead …
Tokyo, Japan, DataM Intelligence: The Japan Coriander Oil Market was valued at USD 5.8 million in 2024 and is projected to reach USD 10.9 million by 2033, growing at a CAGR of 7.1% from 2025 to 2033.
This growth is being fueled by the increasing demand for natural essential oils, rising consumer preference for plant-based and chemical-free products, and the increasing application of coriander oil in cosmetics, aromatherapy, and food flavoring.…
United States Disposable Medical Sensors Market 2025 | Growth Drivers, Key Playe …
Market Size and Growth
The Global Disposable Medical Sensors Market reached US$ 11.7 billion in 2024 and is expected to reach US$ 37.0 billion by 2033, growing at a CAGR of 13.3% during the forecast period 2025-2033.
Key Development:
✅ In September 2025, a leading U.S.-based medical technology company acquired a startup specializing in single-use wearable biosensor patches for remote patient monitoring. The acquisition enhances its portfolio in connected healthcare and strengthens its…
United States Pyrethroid Market 2025 | Growth Drivers, Key Players & Investment …
Market Size and Growth
The global pyrethroid market is expected to exhibit a CAGR of 6.4% during the forecast period (2024-2031).
Recent Global Developments in Pyrethroid Industry
✅ In July 2025, Japan issued a regulatory update revising maximum residue limits (MRLs) for the synthetic pyrethroid Etofenprox across several food categories, including apples and rice. The update aligns Japan's pesticide safety standards with international benchmarks and ensures safer agricultural use.
✅ In April 2025, Jiangsu…
More Releases for PARP
PARP Inhibitors Market to Surpass USD 12 Billion by 2034,
Introduction
Cancer continues to be one of the most pressing healthcare challenges worldwide, and the demand for targeted, effective therapies has never been greater. Among the most promising innovations are Poly (ADP-ribose) polymerase (PARP) inhibitors, a class of drugs designed to exploit DNA repair weaknesses in cancer cells, particularly those with BRCA1/2 mutations. By preventing cancer cells from repairing DNA damage, PARP inhibitors lead to cell death, offering a new line…
PARP Inhibitor Biomarkers Market Size to Expand Lucratively by 2034
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global PARP Inhibitor Biomarkers Market - (By Product (Kits, Assays), By Services (BRCA 1 & 2 Testing, HRD Testing, HRR Testing, Others), By Application (Breast Cancer, Ovarian Cancer, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic, the Global PARP Inhibitor Biomarkers Market is valued at US$ 879.8…
China Market Analysis of PARP Inhibitors: Growth Opportunities
Global PARP Inhibitors Market: Introduction
A PARP (poly ADP-ribose polymerase) inhibitor is a substance that blocks PARP enzyme in the cell. DNA damage occurs during cancer. Blocking of PARP helps the cancer cells in repairing their damaged part of DNA.
Read Report Overview - https://www.transparencymarketresearch.com/parp-inhibitors-market.html
Global PARP Inhibitors Market: Competition Landscape
Key players operating in the global PARP inhibitors market are AstraZeneca, Tesaro, AbbVie Inc., Medivation, and Clovis Oncology. The global market is…
PARP Inhibitors Market Trends and Segments
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). PARP Inhibitors are the drugs, which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors developed for treating several diseases, the most important one is cancer. As several types of cancers rely on PARP than regular cells, which makes it attractive target for treating cancers. These…
PARP Inhibitors Market Dynamics, Segments, Size and Demand, 2017 - 2027
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). PARP Inhibitors are the drugs, which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors developed for treating several diseases, the most important one is cancer. As several types of cancers rely on PARP than regular cells, which makes it attractive target for treating cancers. These…
Global PARP Inhibitor Market: Size, Trends And Forecasts (2016-2020)
Scope of the Report
The report titled Global PARP Inhibitor Market: Size, Trends and Forecasts (2016-2020) provides an in-depth analysis of the global PARP inhibitor market with detailed analysis of market size on the basis of value along with the comprehensive examination of each of the segments of the market, namely, Lynparza, Niraparib, Rucaparib, Talazoparib and Veliparib.
The report analyses the global Lynparza market in detail along with the regional analysis as…
